| BRIDGEBIO PHARMA DL-,001 |
| USA |
| Gesundheit |
| US10806X1028 / A2PLX7 |
| 2CL (Frankfurt) / BBIO (NASDAQ) |
| FRA:2CL, ETR:2CL, 2CL:GR, NASDAQ:BBIO |
| - |
| https://bridgebio.com/ |
|
BridgeBio Pharma, Inc., a commercial-stage biophar..
>Volltext.. |
| 8920.16 Mio. EUR |
| 10555.84 Mio. EUR |
| 202.79 Mio. EUR |
| -550.57 Mio. EUR |
| -667.68 Mio. EUR |
| -3.52 EUR |
| 2302.22 Mio. EUR |
| 644.45 Mio. EUR |
| -563.97 Mio. EUR |
| 4.31 |
| -2.15% |
| -55.56% |
| - |
| - |
| - |
| BRIDGEBIO |
| 27.10.25 |